2 Dividend Stocks to Buy and Hold Forever

P&G reported fiscal 2026 net sales of approximately $87 billion, up 3%, and returned more than $15 billion to shareholders, including $10.2 billion in dividends; organic sales and core EPS each grew 1%. Stryker's Q2 2026 revenue rose 9.4% to $6.6 billion, adjusted EPS increased 17.9% to $3.69, and management raised the lower end of its full-year outlook to 8.3%–9.3% organic sales growth and $14.95–$15.10 adjusted EPS. The article presents P&G as a stable dividend-growth business and Stryker as a faster-growing medical technology company, while noting risks including recalls, acquisition costs, and hospital spending pressures.

Analysis

The more investable distinction is earnings sensitivity, not dividend history. PG’s defensive demand can cushion a downturn, but low underlying growth leaves returns more exposed to pricing, mix, input costs, foreign exchange, and private-label substitution; a dividend record alone does not protect the multiple if price increases stop translating into profit growth. For SYK, the key second-order question is whether robotic-system adoption deepens surgeon and hospital preference for its implant ecosystem and supports repeat procedure volumes—or whether utilization and hospital budget constraints limit the payoff from equipment placements. Competition from Zimmer Biomet and Johnson & Johnson makes adoption and procedure data more informative than the aging-population narrative.

Over the next 1–3 months, watch SYK’s organic growth, procedure trends, and guidance revisions, alongside PG’s volume/mix and pricing commentary. Over 6–18 months, sustained SYK adoption could support a better growth profile, while persistent low volume growth at PG would make it increasingly bond-proxy-like. The article provides no valuation or relative-multiple context, so it does not establish that either stock is attractively priced. The contrarian risk is that the defensive dividend framing understates PG’s growth ceiling, while the demographic thesis overstates how quickly population aging converts into paid procedures and earnings.

Key Decisions for Investors

• Do not buy PG solely for its dividend streak. Treat it as a defensive exposure only if pricing continues to offset cost and mix pressures; reassess if organic volume weakens alongside price realization.
• Keep SYK on a growth watchlist rather than chasing the demographic narrative. Consider adding on weakness only if procedure growth and guidance remain firm and valuation is reasonable versus its own history and peers.
• A conditional relative-value expression is long SYK versus PG if SYK earnings revisions continue to improve and its relative valuation is not already stretched. Reduce or exit if SYK cuts its outlook, procedure trends soften, or robotic-platform adoption fails to translate into operating results.
• Before acting, verify current valuation, dividend yield, cash-flow conversion, and—especially for SYK—procedure growth, system utilization, and recall or acquisition-related costs; the article does not provide enough information to set entry levels or quantify risk/reward.